{
    "organizations": [],
    "uuid": "2c9e40fbc18b59f5ee3aa83ddb959c0dc98efdbe",
    "author": "",
    "url": "https://www.reuters.com/article/brief-intellia-therapeutics-inc-q1-loss/brief-intellia-therapeutics-inc-q1-loss-per-share-0-51-idUSASC09YJU",
    "ord_in_thread": 0,
    "title": "BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1, 2018 / 11:36 AM / Updated 5 minutes ago BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51 Reuters Staff\nMay 1 (Reuters) - Intellia Therapeutics Inc:\n* INTELLIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* ANTICIPATES SUBMITTING ITS IN VIVO INVESTIGATIONAL NEW DRUG APPLICATION BY END OF 2019 * QTRLY LOSS PER SHARE $0.51\n* $328 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018\n* CONFIRMS PLANS TO INITIATE IND-ENABLING STUDIES IN MID-2018 FOR ITS LEAD INDICATION, TRANSTHYRETIN AMYLOIDOSIS\n* INTELLIA PLANS TO SHARE PRECLINICAL DATA ON BOTH IMMUNO-ONCOLOGY AND AUTOIMMUNE DISEASE TARGETS IN 2018\n* COLLABORATION REVENUE WAS $7.5 MILLION FOR Q1 OF 2018, COMPARED TO $6.2 MILLION DURING Q1 OF 2017\n* Q1 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $6.3 MILLION â€” THOMSON REUTERS I/B/E/S\n* INTELLIA - EXPECTS CASH, CASH EQUIVALENTS AS OF MARCH 31, 2018 WILL ENABLE CO TO FUND OPERATING EXPENSES AND CAPEX THROUGH MID-2020 Source text for Eikon: Further company coverage:",
    "published": "2018-05-01T14:34:00.000+03:00",
    "crawled": "2018-05-01T14:57:12.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "inc",
        "q1",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "intellia",
        "therapeutic",
        "inc",
        "intellia",
        "therapeutic",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "anticipates",
        "submitting",
        "vivo",
        "investigational",
        "new",
        "drug",
        "application",
        "end",
        "qtrly",
        "loss",
        "per",
        "share",
        "million",
        "cash",
        "cash",
        "equivalent",
        "march",
        "confirms",
        "plan",
        "initiate",
        "study",
        "lead",
        "indication",
        "transthyretin",
        "amyloidosis",
        "intellia",
        "plan",
        "share",
        "preclinical",
        "data",
        "autoimmune",
        "disease",
        "target",
        "collaboration",
        "revenue",
        "million",
        "q1",
        "compared",
        "million",
        "q1",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "intellia",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "march",
        "enable",
        "co",
        "fund",
        "operating",
        "expense",
        "capex",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}